Category: ~$80M

  • Grifols Acquires Remaining 56% of GigaGen for ~$80M

    Shots: Grifols acquires the remaining 56% share of GigaGen for $80M. The acquisition will add GigaGen’s pipeline of recombinant polyclonal Abs, including GIGA-2050 and boost Grifol’s portfolio if I-O therapies Earlier, in 2017, Grifols acquired a 44% stake in GigaGen, when the two companies collaborated to develop polyclonal antibodies under a $50M pact GIGA-2050 is […]